hypermethylation of repetitive genomic sequences probably prevents chromosomal instability, translocations, and gene disruption caused by the reactivation of transposable DNA sequences. 32 Cells that lack the stabilizing effect of DNA methylation because they have spontaneous defects in DNA methyltransferases (DNMTs) 33 or experimentally disrupted DNMTs 34 have prominent nuclear abnormalities.
DNA methylation occurs in the context of chemical modifications of histone proteins. 35 Histones are not merely DNA-packaging proteins, but molecular structures that participate in the regulation of gene expression. They store epigenetic information through such post-translational modifications as lysine acetylation, arginine and lysine methylation, and serine phosphorylation. These modifications affect gene transcription and DNA repair. It has been proposed that distinct histone modifications form a "histone code." 36 Acetylation of histone lysines, for example, is generally associated with transcriptional activation. 15, 16 The functional consequences of the methylation of histones depends on the type of residue -lysine (K) or arginine -and the specific site that the methylation modifies (e.g., K4, K9, or K20). 15, 16 Methylation of H3 at K4 is closely linked to transcriptional activation, 37 whereas methylation of H3 at K9 or K27 and of H4 at K20 is associated with transcriptional repression. What emerges from these findings is a flexible but precise pattern of DNA methylation and histone modification that is essential for the physiologic activities of cells and tissues.
DNA H y p ome th y l at ion in T umor s
The low level of DNA methylation in tumors as compared with the level of DNA methylation in their normal-tissue counterparts was one of the first epigenetic alterations to be found in human cancer. 5 The loss of methylation is mainly due to hypomethylation of repetitive DNA sequences and demethylation of coding regions and intronsregions of DNA that allow alternative versions of the messenger RNA (mRNA) that is transcribed from a gene. 38 A recent large-scale study of DNA methylation with the use of genomic microarrays has detected extensive hypomethylated genomic regions in gene-poor areas. 24 During the development of a neoplasm, the degree of hypomethylation of genomic DNA increases as the lesion progresses from a benign proliferation of cells to an invasive cancer 39 (Fig. 1) .
Three mechanisms have been proposed to ex-plain the contribution of DNA hypomethylation to the development of a cancer cell: generation of chromosomal instability, reactivation of transposable elements, and loss of imprinting. Undermethylation of DNA can favor mitotic recombination, leading to deletions and translocations, 40 and it can also promote chromosomal rearrangements. This mechanism was seen in experiments in which the depletion of DNA methylation by the disruption of DNMTs 37 caused aneuploidy. Hypomethylation of DNA in malignant cells can reactivate intragenomic endoparasitic DNA, such as L1 (long interspersed nuclear elements), and Alu (recombinogenic sequence) repeats. 32 These undermethylated transposons can be transcribed or translocated to other genomic regions, thereby further disrupting the genome. The loss of methyl groups from DNA can also disrupt genomic imprinting. In the hereditary Beckwith-Wiedemann syndrome (a syndrome characterized by exomphalos, macroglossia, and gigantism), for example, there is loss of imprinting of IGF2 (the insulin-like growth factor gene) and an increased risk of cancer. 41 Loss of imprinting of IGF2 is also a risk factor for colorectal cancer, 42,43 and disrupted genomic imprinting contributes to the development of Wilms' tumor. 41 In animal models, mice with a loss of imprinting of A multistage model of carcinogenesis in skin is shown. In conjunction with phenotypic cellular changes and the accumulation of genetic defects, there is a progressive loss of total DNA methylation content, an increased frequency of hypermethylated CpG islands, and an increased histone-modification imbalance in the development of the disease. H-ras denotes Harvey-ras oncogene, and 5mC 5-methylcytosine.
IGF2 44 or overall defects in imprinting 45 have an increased risk of cancer. Normally, certain testisspecific genes, genes that encode melanoma antigens, or specific proliferation-linked genes 38 are silent in somatic cells because promoter-region CpG islands are methylated. In some cancer cells, by contrast, these promoter regions undergo demethylation, and the usually repressed genes become expressed. Two notable examples of the hypomethylation mechanism are the activation of PAX2 (a gene that encodes a transcription factor involved in proliferation and other important activities of cells) and the activation of the let-7a-3 miRNA gene, which has been implicated in endometrial and colon cancer. 46, 47 The hypomethylation of DNA can have unpredictable effects. The progeny of a mouse deficient in DNA methylation and a Min mouse, which has a genetic defect in the adenomatous polyposis coli (APC) gene and is prone to colon adenoma, have fewer tumors than one would expect 48 ; by contrast, another DNMT-defective mouse strain has an increased risk of lymphoma. 49 Moreover, hypomethylation suppresses the later stages of intestinal tumorigenesis 48 but promotes early precancerous lesions in the colon and liver through genomic deletions. 50
Inac t i vat ion of T umorSuppr e s s or Gene s
Hypermethylation of the CpG islands in the promoter regions of tumor-suppressor genes is a major event in the origin of many cancers. The initial reports of hypermethylation of the CpG islands in the promoter region of the retinoblastoma tumorsuppressor gene (Rb) 6,7 were followed by the findings that hypermethylation of the CpG island was a mechanism of inactivation of the tumor-suppressor genes VHL (associated with von Hippel-Lindau disease), p16
INK4a
, [8] [9] [10] [11] hMLH1 (a homologue of MutL Escherichia coli), 26 and BRCA1 (breast-cancer susceptibility gene 1). 26, 51 Hypermethylation of the CpG-island promoter can affect genes involved in the cell cycle, DNA repair, the metabolism of carcinogens, cell-to-cell interaction, apoptosis, and angiogenesis, all of which are involved in the development of cancer. 22, 26 Hypermethylation occurs at different stages in the development of cancer and in different cellular networks, and it interacts with genetic lesions (Table 1) . Such interactions can be seen when hypermethylation inactivates the CpG island of the promoter of the DNA-repair genes hMLH1, BRCA1, MGMT (O 6 -methylguanine-DNA methyltransferase), and the gene associated with Werner's syndrome (WRN). 26, [51] [52] [53] In each case, silencing of the DNA-repair gene blocks the repair of genetic mistakes, thereby opening the way to neoplastic transformation of the cell.
The profiles of hypermethylation of the CpG islands in tumor-suppressor genes are specific to the cancer type 54,55 ( Fig. 2 and Table 1 ). Each tumor type can be assigned a specific, defining DNA "hypermethylome." Such patterns of epigenetic inactivation occur not only in sporadic tumors but also in inherited cancer syndromes, 56 in which hypermethylation can be the second lesion in Knudson's two-hit model of how cancer develops. 56, 57 Recently devised epigenomic techniques have revealed maps of hypermethylation of the CpG islands that suggest the occurrence of 100 to 400 hypermethylated CpG islands in the promoter regions of a given tumor. 22 We still do not understand how CpG islands become hypermethylated in some types of cancer but not in others. Inactivation of a particular gene by methylation could give certain tumor types a growth advantage. CpG islands can have a location within a particular nucleotide sequence that allows them to become hypermethylated, 24 or they can be located in a chromosomal region that is subject to large-scale epigenetic dysregulation. 22 In addition, there is a mechanism in which modifications of histones mark a gene for hypermethylation. This marking occurs in the binding of the methyltransferase enhancer of zeste drosophila homologue 2 (EZH2), a component of the polycomb family of gene-silencing proteins, 58,59 to histones in stem cells with unmethylated gene promoters 60-62 and in the histone-associated silencing of p16
INK4a in colon-cancer cells. 63
His t one Modific at ions of C a ncer Cel l s
Mass spectrometry, the most reliable method for detecting changes in histones, is time-consuming and highly specialized. 22 Moreover, histone modifications occur in different histone proteins, histone variants (e.g., H3.3), and histone residues such as lysine, arginine, and serine. These modifications also involve different chemical groups (e.g., methyl, acetyl, and phosphate) and have different degrees of methylation (e.g., monomethylation, dimethylation, and trimethylation). Acetylation and methylation of histones have direct effects on a variety of nuclear processes, including gene transcription, DNA repair, DNA replication, and the organization of chromosomes. Generally, histone acetylation is associated with transcriptional activation, 15,16 but the effect of histone methylation depends on the type of amino acid and its position in the histone tail. 15,16 The many permutations and combinations form a complex web of histone modifications.
Hypermethylation of the CpG islands in the promoter regions of tumor-suppressor genes in cancer cells is associated with a particular combination of histone markers: deacetylation of histones H3 and H4, loss of H3K4 trimethylation, and gain of H3K9 methylation and H3K27 trimethylation. 23, 64 The presence of the hypo-acetylated and hypermethylated histones H3 and H4 65 silences certain genes with tumor-suppressor-like properties, such as p21 WAF1 , despite the absence of hypermethylation of the CpG island. In human tumors generally, modifications of histone H4 entail a loss of monoacetylated and trimethylated forms. 18 These changes appear early and accumulate dur- ing the development of the tumor 18 (Fig. 1) . The losses occur predominantly at the monoacetylated Lys16 and trimethylated Lys20 residues of histone H4 in association with hypomethylated repetitive DNA sequences. 18 They have been found in breast and liver cancer. 66, 67 In prostate cancer, weak immunohistochemical staining of two histone modifications (the dimethylation of lysine 4 and the acetylation of lysine 18 of histone H3) has been proposed as a marker of a high risk of recurrence. 19 There are also genetic lesions to consider in the aberrant epigenetic landscape of the cancer cell ( Fig. 3 Gray cylinders indicate octamers of histones, consisting of histones H2A, H2B, H3, and H4. They form the nucleosomes, and the double strand of DNA is wrapped around them. A combination of selection and targeted disruption of the DNA methylation and histone-modifier proteins disrupts the epigenetic circumstances in the cancer cell. Epigenetic inactivation of tumor-suppressor genes is associated with dense CpG-island promoter hypermethylation and the appearance of repressive histone markers such as methylation of lysines 9 and 27 of histone H3. Epigenetic drugs can partially restore the distorted epigenetic picture by removing inactivation markers (e.g., DNA methylation) and inducing the presence of active markers (e.g., histone acetylation). AC denotes acetylation, DNMTs DNA methyltransferases, HATs histone acetyltransferases, HDAC histone deacetylase, HDMs histone demethylases, HMTs histone methyltransferases, MBDs methyl-CpG-binding domain proteins, Met-K4 methylation of lysine 4, Met-K9 methylation of lysine 9, Met-K27 methylation of lysine 27, Sirt1 sirtuin 1, and Swi/SNF switching/sucrose nonfermenting chromatin-remodeling complex. Recent studies have shown that profiles of miRNA expression differ between normal tissues and tumor tissues and among tumor types. 72-74 Down-regulation of subgroups of miRNAs, a common finding, 72-74 implies a tumor-suppressor function for miRNAs, 72,73 as in the examples of downregulated let-7 and miR-15/miR-16, which target the RAS and BCL2 oncogenes, respectively. 75, 76 DNA hypermethylation in the miRNA 5 regulatory region is a mechanism that can account for the down-regulation of miRNA in tumors. 12,13 In colon-cancer cells with disrupted DNMTs, hypermethylation of the CpG island does not occur in miRNAs. 13 The methylation silencing of miR-124a also causes activation of the cyclin D-kinase 6 oncogene (CDK6), 13 and it is a common epigenetic lesion in tumors. 13 Epigene t ic s in C a ncer M a nage men t
The DNA-methylation and histone-modification patterns associated with the development and progression of cancer have potential clinical use. DNA hypermethylation markers are under study as complementary diagnostic tools, prognostic factors, and predictors of responses to treatment (Fig. 4) . For instance, the glutathione S-transferase gene (GSTP1) is hypermethylated in 80 to 90% of patients with prostate cancer, 77-79 but it is not hypermethylated in benign hyperplastic prostate tissue. 80 Thus, the detection of GSTP1 methylation could help to distinguish between prostate cancer and a benign process. Hypermethylation of CpG islands can be a marker of cancer cells in all types of biologic fluids and biopsy specimens, 21,81 making detection of GSTP1 methylation in urine 79,82 a possible clinical application. Analysis of hypermethylation of the CpG island has potential diagnostic applicability for carriers of high-penetrance mutations in tumor-suppressor genes. For example, identification of DNA hypermethylation in a breast-biopsy specimen from a carrier of a BRCA1 mutation could be useful when the pathological diagnosis is uncertain, because hypermethylation of the CpG island is an early event in the development of cancer. 56 Analysis of several hypermethylated genes detects twice as many tumor cells in breast ductal fluids as conventional cytologic analysis, 83 and hypermethylated genes can be found in exfoliated cells at different stages in the development of cervical cancer. 84 The application of DNA-hypermethylation markers as tumor markers in routine clinical practice will require rapid, quantitative, accurate, and cost-effective techniques and objective criteria for selection of the genes that are applicable to different tumor types.
Hypermethylation of a tumor-suppressor gene and DNA hypermethylome profiles can be indicators of the prognosis in patients with cancer. Hypermethylation of the death-associated protein kinase (DAPK), p16
INK4a
, and epithelial membrane protein 3 (EMP3) has been linked to poor outcomes in lung, colorectal, and brain cancer, respectively. 22 Prognostic dendrograms similar to those used in gene-expression microarray analyses, with the use of a combination of hypermethylated markers and CpG-island microarrays, have been developed. 22 These epigenomic profiles are complementary to profiles of gene-expression patterns and can be developed with DNA extracted from archived material. 21, 22 The hypermethylation of particular genes is potentially a predictor of the response to treatment. The methylation-associated silencing of the gene for the DNA-repair protein MGMT in gliomas is an example. 85 MGMT reverses the addition of alkyl groups to the guanine base of DNA and is thus a point of attack for alkylating agents. 52 Two studies have shown that the hypermethylation of MGMT is an independent predictor of a favorable response of gliomas to carmustine (BCNU) 86 or temozolomide. 87 These findings have been confirmed by others. 88 Moreover, the hypermethylation of MGMT in untreated patents with low-grade astrocytoma and other tumor types is a marker of a poor prognosis, 89,90 and it is probably related to the accumulation of mutations in these tumors. 90 The potential of the methylation status of MGMT and other DNA-repair genes to predict the response to chemotherapy has also been seen with cyclophosphamide (with the MGMT gene), 91 cisplatin (with the hMLH1 gene), 92 methotrexate (with the reduced folate carrier [RFC] gene), 93 and irinotecan (with the WRN gene). 53
Epigene t ic Ther a py of c a ncer
Unlike mutations, DNA methylation and histone modifications are reversible. Epigenetic alterations allow the cancer cell to adapt to changes in its microenvironment, but dormant, hypermethylated tumor-suppressor genes can be awakened with drugs (Fig. 3) . It is possible to re-express DNAmethylated genes in cancer cell lines by using demethylating agents 94 and to rescue their functionality. 22,26 DNA demethylating drugs in low doses have clinical activity against some tumors. Two such agents, 5-azacytidine (Vidaza) and 5-aza-2 -deoxycytidine (decitabine), have been approved as treatments for the myelodysplastic syndrome and leukemia. 15, 95, 96 However, these demethylating agents have not yet been shown to have clinical activity against solid tumors. 15 Histone deacetylase (HDAC) inhibitors 97 can induce differentiation, cell-cycle arrest, and apoptosis in vitro, 97 although it has not been possible to pinpoint a specific mechanism that explains these effects. 97, 98 In clinical trials, HDAC inhibitors are associated with a low incidence of adverse events. 15 The first drug of this type, suberoylanilide hydroxamic acid (vorinostat), has been approved by the Food and Drug Administration for the treatment of cutaneous T-cell lymphoma. 99 The efficacy of HDAC inhibitors in the treatment of other tumors is limited.
The nonspecific effects of DNA demethylating agents and HDAC inhibitors could have unintended consequences with regard to gene expression, and as a paradoxical result, they could have growth-promoting effects on a tumor. However, there are prospects for directed epigenetic-specific therapy with the use of transcription factors that target particular gene promoters. 100 For instance, the engineered zinc finger proteins target unique sequences in the MASPIN promoter; these proteins not only reactivate the epigenetically silenced gene but also inhibit tumor growth in vitro. 101 Until now, therapy with DNA demethylating agents and HDAC inhibitors has been based on classic protein-coding tumor-suppressor genes, but the possibility of rescuing the growth-inhibitory effects of miRNAs by means of DNA-demethylation treatment 12,13 suggests new epigenetic treatment strategies that are worthy of further exploration.
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